IP Library Granted Patent US 11,890,328
Granted Patent B2
US 11,890,328 · App. 17/360,674 · Granted Feb 6, 2024

Fibroin-derived protein composition

Inventors: Brian D. Lawrence (Plymouth, MN); David W. Infanger (Plymouth, MN)
Assignee: Silk Technologies, Ltd.
A61K38/39A23J3/00A23L2/66A23L33/17A61K35/64A61K45/06C07K14/78A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,890,328
App. No.
17/360,674
Granted
Feb 6, 2024
Kind
B2
Abstract

A protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.

Claims (22)

1. A method of treating dry eye syndrome in a subject comprising administering an effective amount of a protein composition to an eye of the subject, thereby treating the dry eye disease, wherein the protein composition is formulated as an ophthalmic formulation comprising water; wherein the protein composition is a fibroin-derived protein composition prepared by a process comprising heating an aqueous fibroin solution at an elevated pressure, wherein:

the aqueous fibroin solution comprises lithium bromide at a concentration of at least about 8M, and the aqueous fibroin solution is heated to at least about 105° C. (221° F.) under a pressure of about 10 PSI to about 20 PSI for at least about 20 minutes in the presence of the lithium bromide;

to provide a protein composition comprising fibroin-derived protein wherein:

the primary amino acid sequences of the fibroin-derived protein composition differ from native fibroin by at least by at least 4% with respect to the combined amino acid content of serine, glycine, and alanine, based on the combined absolute values of the differences in the content of serine, glycine, and alanine;

cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains of fibroin are reduced or eliminated;

the protein composition has a serine content that is reduced by greater than 25% compared to native fibroin protein; and

wherein the average molecular weight of the fibroin-derived protein composition is less than about 100 kDa.

2. The method of claim 1 wherein the protein composition comprises about 0.1% to about 10% by weight of the ophthalmic formulation.

3. The method of claim 2 wherein the protein composition comprises one or more of a buffering agent, a stabilizing agent, and a demulcent.

4. The method of claim 3 wherein the demulcent is one or more of hyaluronic acid (HA), hydroxyethyl cellulose, hydroxypropyl methylcellulose, dextran, gelatin, a polyol, carboxymethyl cellulose (CMC), polyethylene glycol, propylene glycol (PG), hypromellose, glycerin, polysorbate 80, polyvinyl alcohol, and povidone, and wherein the buffering agent is one or more of phosphate buffered saline, borate buffered saline, citrate buffer saline, sodium chloride, calcium chloride, magnesium chloride, potassium chloride, sodium bicarbonate, zinc chloride, hydrochloric acid, sodium hydroxide, and edetate disodium.

5. The method of claim 1 wherein the aqueous fibroin solution is heated to a temperature of about 115° C. (239° F.) to about 125° C. (257° F.) under a pressure of about 15 PSI to about 20 PSI for at least about 30 minutes.

6. The method of claim 1 wherein the fibroin-derived protein has an average molecular weight of less than about 60 kDa.

7. The method of claim 1 wherein the protein composition has an aqueous viscosity of less than 5 cP as a 10% w/w solution in water.

8. The method of claim 1 wherein the protein composition has an aqueous viscosity of less than 10 cP as a 24% w/w solution in water.

9. The method of claim 1 wherein the fibroin-derived protein comprises between 4.5% and 7.5% serine amino acid residues.

10. The method of claim 1 wherein a primary amino acid sequences of the fibroin-derived protein differ from native fibroin by at least 8% with respect to the combined amino acid content of serine, glycine, and alanine based on a combined absolute values of the differences in the content of serine, glycine, and alanine.

11. The method of claim 1 wherein the fibroin-derived protein comprises less than 8.5% serine amino acid residues.

12. The method of claim 11 wherein the fibroin-derived protein comprises less than 6% serine amino acid residues.

13. The method of claim 1 wherein the fibroin-derived protein comprises greater than 46.5% glycine amino acids.

14. The method of claim 13 wherein the fibroin-derived protein comprises greater than 48% glycine amino acids.

15. The method of claim 1 wherein the fibroin-derived protein comprises greater than 30% alanine amino acids.

16. The method of claim 15 wherein the fibroin-derived protein comprises greater than 31.5% alanine amino acids.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE SPELLING OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 058374 FRAME 0991. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 22, 2021
From: LAWRENCE, BRIAN D.; INFANGER, DAVID W.
To: SILK TECHNOLOGIES, LTD.
Reel/Frame 058568/0441 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2021
From: LAWRENCE, BRIAN D.; INFANGER, DAVID W.
To: SILK TECNOLOGIES, LTD.
Reel/Frame 058374/0991 →
Continuity (7)
Continuation 16680186 · Nov 11, 2019
Continuation 15912295 · Mar 5, 2018
Continuation 15212086 · Jul 15, 2016
Continuation 14831473 · Aug 20, 2015
Provisional Application 62193790 · Jul 17, 2015
Provisional Application 62039675 · Aug 20, 2014
Related Publication 20220054596A1 · Feb 24, 2022